STAAR Surgical (NASDAQ:STAA – Get Free Report) major shareholder Broadwood Partners, L.P. bought 21,155 shares of the firm’s stock in a transaction on Tuesday, January 14th. The stock was purchased at an average cost of $21.46 per share, with a total value of $453,986.30. Following the completion of the acquisition, the insider now directly owns 10,869,786 shares of the company’s stock, valued at approximately $233,265,607.56. The trade was a 0.20 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Broadwood Partners, L.P. also recently made the following trade(s):
- On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The shares were purchased at an average cost of $21.50 per share, with a total value of $176,751.50.
- On Wednesday, December 18th, Broadwood Partners, L.P. acquired 23,000 shares of STAAR Surgical stock. The stock was acquired at an average cost of $24.33 per share, for a total transaction of $559,590.00.
- On Monday, December 16th, Broadwood Partners, L.P. bought 53,500 shares of STAAR Surgical stock. The stock was acquired at an average cost of $24.24 per share, with a total value of $1,296,840.00.
STAAR Surgical Trading Up 0.6 %
NASDAQ STAA traded up $0.14 on Thursday, hitting $21.85. 531,485 shares of the company traded hands, compared to its average volume of 732,698. The business’s 50 day moving average price is $25.72 and its 200-day moving average price is $32.16. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of 49.66 and a beta of 0.63. STAAR Surgical has a 52-week low of $21.13 and a 52-week high of $52.68.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several equities research analysts recently commented on STAA shares. Stephens raised STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Tuesday, January 7th. Finally, Canaccord Genuity Group lowered their price objective on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a research report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, STAAR Surgical has a consensus rating of “Hold” and a consensus target price of $42.83.
Check Out Our Latest Report on STAAR Surgical
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Read More
- Five stocks we like better than STAAR Surgical
- What Makes a Stock a Good Dividend Stock?
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Want to Profit on the Downtrend? Downtrends, Explained.
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- How to Start Investing in Real Estate
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.